• Genexine will hold an extraordinary shareholders’ meeting on Nov. 20, 2026 at 9:00 a.m. in Seoul.
• Agenda includes amending the articles of incorporation to add new business purposes tied to medical AI, data centers, cloud, AI infrastructure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genexine Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261006900383), on October 06, 2026, and is solely responsible for the information contained therein.